For the quarter ending 2025-09-30, CNTX had -$6,578,864 decrease in cash & cash equivalents over the period. -$6,578,864 in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Operating expenses-CTIM76 | 4,167,318 | - |
| Operating expenses-CT95 | 3,491,014 | - |
| Operating expenses-CT202 | 8,930,266 | - |
| Personnel-related costs | 5,414,250 | - |
| Professional fees | 1,642,602 | - |
| Share-based compensation | 1,005,912 | - |
| Other segment items | 1,246,623 | - |
| Loss from operations | -10,610,480 | - |
| Interest income | 833,772 | - |
| Other income (expense) | 83,471 | - |
| Net loss | -9,693,237 | -13,404,771 |
| Acquired in-process research and development charge | 0 | - |
| Share-based compensation expense | 323,081 | 682,831 |
| Depreciation and amortization expense | 4,066 | 8,120 |
| Reduction in the carrying amount of operating lease right-of-use asset | 27,457 | 52,737 |
| Prepaid expenses and other current assets | -1,310,554 | -34,972 |
| Accounts payable | 324,996 | 958,960 |
| Accrued expenses and other current liabilities | 1,151,338 | 855,651 |
| Operating lease liability | -27,119 | -52,061 |
| Cash used in operating activities | -6,578,864 | -10,863,561 |
| Acquired in-process research and development | 0 | - |
| Purchase of property and equipment | 0 | 33,948 |
| Cash used in investing activities | 0 | -33,948 |
| Payment of offering costs from the sale of common stock from atm facility | 0 | 15,268 |
| Proceeds from the sale of common stock and prefunded warrants, net | 0 | 0 |
| Cash (used in) provided by financing activities | 0 | -15,268 |
| Net (decrease) increase in cash and cash equivalents | -6,578,864 | -10,912,777 |
| Cash and cash equivalents at beginning of period | 94,429,824 | - |
| Cash and cash equivalents at end of period | 76,938,183 | - |
Context Therapeutics Inc. (CNTX)
Context Therapeutics Inc. (CNTX)